Aenova and Haupt Pharma To Merge - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Aenova and Haupt Pharma To Merge

The Aenova Group, a provider of development and manufacturing services for medicines and dietary supplements reported it will merge with Haupt Pharma, a company specializing in contract development and manufacturing. An agreement has been signed, but the purchase price remains confidential. The transaction will proceed subject to the approval of the relevant competition authorities, but is expected to become legally binding at the end of 2013.

The merger will add areas such as sterile manufacturing and the production of special active ingredients (including hormones, antibiotics, and cytostatics) to Aenova.

Aenova’s network will increase from eight to 21 sites including production facilities in Germany (Berlin, Brackenheim, Münster, Gronau, Regensburg, Wolfratshausen) and in Europe, its first site in Japan. The number of employees will increase from 2,500 to more than 4,000.

Source: Aenova Group


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here